Bicara Therapeutics Inc (BCAX) PT Raised to $39 at BTIG

BTIG analyst Jeet Mukherjee raised the price target on Bicara Therapeutics Inc (NASDAQ: BCAX) to $39.00 (from $28.00) while maintaining a Buy rating.

The analyst commented: "BCAX reported 2Q26 earnings this morning. The stock traded down ~14% on the back of several leadership changes, most notably Ryan Cohlhepp (President & COO) succeeding Claire Mazumdar as CEO in January of next year. We see the sell-off as less to do with the leadership changes themselves, and more to do with the negative readthrough to near-term M&A potential. These leadership changes were expected and natural as the co transitions to a commercial-stage one. On ficera, the co has started the FORTIFI-FLEX trial testing a QW loading and Q3W maintenance strategy, with results expected in time for a potential accelerated approval. FORTIFI-HN01 ph 3 enrollment remains on track for substantial completion by YE and a mid-2027 interim analysis. Cash of $497M holds runway into 1H29, and the next key catalyst is ph 1b mCRC data, expected 2H26. We are also raising our PT to $39 from $28, driven by increased commercial ramp and peak penetration assumptions reflecting ficera's improving commercial competitiveness on the back of the latest ASCO data and the new loading/maintenance dosing format. Reiterate Buy rating."

You May Also Be Interested In

• Pizza Hut CEO Aaron Powell resigns
• Raymond James Resumes Ally Financial (ALLY) at Strong Buy
• Stifel Starts Taiwan Semi (TSM) at Buy